Vertex Pharmaceuticals (WBO:VRTX) EV-to-Revenue : 9.43 (As of Apr. 26, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Vertex Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Vertex Pharmaceuticals's enterprise value is €86,343 Mil. Vertex Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €9,155 Mil. Therefore, Vertex Pharmaceuticals's EV-to-Revenue for today is 9.43.

The historical rank and industry rank for Vertex Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

WBO:VRTX' s EV-to-Revenue Range Over the Past 10 Years
Min: 5.66 Med: 13.3 Max: 52.92
Current: 9.36

During the past 13 years, the highest EV-to-Revenue of Vertex Pharmaceuticals was 52.92. The lowest was 5.66. And the median was 13.30.

WBO:VRTX's EV-to-Revenue is ranked worse than
55.28% of 1033 companies
in the Biotechnology industry
Industry Median: 7.63 vs WBO:VRTX: 9.36

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-26), Vertex Pharmaceuticals's stock price is €367.65. Vertex Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €35.14. Therefore, Vertex Pharmaceuticals's PS Ratio for today is 10.46.

Vertex Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Vertex Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals EV-to-Revenue Chart

Vertex Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

12.87

8.97

6.51

7.20

9.57

Vertex Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															7.20	7.77	8.44	8.13	9.57

Competitive Comparison of Vertex Pharmaceuticals's EV-to-Revenue

For the Biotechnology subindustry, Vertex Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vertex Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's EV-to-Revenue falls into.

Vertex Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Vertex Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	86343.127	/	9155.058
	=	9.43

Vertex Pharmaceuticals's current Enterprise Value is €86,343 Mil.
Vertex Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €9,155 Mil.

Vertex Pharmaceuticals (WBO:VRTX) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Vertex Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	367.65	/	35.14
	=	10.46

Vertex Pharmaceuticals's share price for today is €367.65.
Vertex Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €35.14.

Vertex Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Vertex Pharmaceuticals (WBO:VRTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (WBO:VRTX) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

VRTX:USA VRTX:Mexico 1VRTX:Italy VX1d:UK VX1:Germany VRTX34:Brazil

Address

50 Northern Avenue, Boston, MA, USA, 02210

Website

https://www.vrtx.com

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.